Compare DCGO & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCGO | ATYR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | 58 |
| Industry | Managed Health Care | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 82.6M |
| IPO Year | 2020 | N/A |
| Metric | DCGO | ATYR |
|---|---|---|
| Price | $0.68 | $0.84 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 9 |
| Target Price | $2.38 | ★ $3.67 |
| AVG Volume (30 Days) | ★ 1.0M | 821.7K |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $322,196,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.49 | $0.64 |
| 52 Week High | $2.45 | $7.29 |
| Indicator | DCGO | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 53.25 | 53.23 |
| Support Level | $0.64 | $0.67 |
| Resistance Level | $0.75 | $0.86 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 70.24 | 73.05 |
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has two reporting segments: Mobile Health Services and Transportation Services. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).